Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Anne B. Chang, Charles Darwin University, Australia

*CORRESPONDENCE Mauricio Tomas Caballero mcaballero@infant.org.ar

SPECIALTY SECTION

This article was submitted to Pediatric Pulmonology, a section of the journal Frontiers in Pediatrics

RECEIVED 02 December 2022 ACCEPTED 12 December 2022 PUBLISHED 06 January 2023

CITATION

Hijano DR, Alvarez-Paggi D and Caballero MT (2023) Editorial: Translational research in pediatric respiratory diseases: From bench to bedside.

Front. Pediatr. 10:1114549. doi: 10.3389/fped.2022.1114549

COPYRIGHT

© 2023 Hijano, Alvarez-Paggi and Caballero. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: Translational research in pediatric respiratory diseases: From bench to bedside

Diego R. Hijano¹, Damián Alvarez-Paggi^{2,3} and Mauricio T. Caballero^{2,3*}

¹Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, United States, ²Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina, ³Fundación INFANT, Buenos Aires, Argentina

KEYWORDS

bronchiolitis, respiratory syncytal virus, ashtma, cystic fibrosis, sinusitis, CLCA1, translational research, respiratory diseases

Editorial on the Research Topic

Translational research in pediatric respiratory diseases: From bench to bedside

Acute and chronic respiratory diseases account for the majority of the morbidity and mortality burden in children worldwide (1). Translational research can provide a more accurate understanding of pathophysiological mechanisms of illnesses, allowing to design new preventative, diagnosis and treatment strategies faster than by basic or clinical approaches alone (2, 3). Several respiratory diseases have clinical presentations that are far from uniform (4). For instance, bronchiolitis presents with overlapping symptoms of varying intensity and these variations can be observed with more than a dozen of viruses with different clinical phenotypes (4). Similarly, the syndrome we refer to as asthma can be a consequence of a wide range of different underlying mechanisms of disease (3). For that reason, we developed a translational research topic to bring together influential researchers in the field of pulmonary diseases in pediatrics encompassing a bench-to-bedside approach. The collection of articles included in this special issue reflect our vision on how to advance the field of respiratory health in children.

The role of toll-like receptor 4 (TLR4) D299G single nucleotide polymorphism (snp) in the severity of respiratory syncytial virus (RSV) has been well described during recent years (5). This TLR4 snp generates an amino acid substitution in the ectodomain associated with an alteration of the responses to different stimuli (5). Low exposure to endotoxins in infants with D299G snp presents a 9-fold greater risk of hospitalization due to RSV infection vs. the rest of the term population (6). Ascaris lumbricoides infection is common in tropical countries and it has been associated with asthma and recurrent wheezing (7, 8). On the grounds of this, Buendía et al. have explored in this topic supplement the association between this TLR4 snp in infants with Ascaris lumbricoides infection and RSV-associated disease severity (9). Interestingly, the authors have found that although positive anti-Ascaris IgE levels in serum were significantly associated with the probability of developing severe bronchiolitis, the

presence of anti-Ascaris antibodies in the subgroup of infants with TLR4 D299G snp was significantly associated with associated with lower risk of severe bronchiolitis due to RSV (9). This finding adds supportive data for future characterization of infants with TLR4 snp. Furthermore, the detection of TLR4 D299G snp might be a relevant screening tool to assess risk for severe disease, as well as interventions under development against RSV disease.

Lopez et al. used clinical, virologic and immunologic data to diagnose bacterial sinusitis by predicting the presence of bacteria in the nasopharynx (10). They enrolled 174 children between 2 and 12 years of age with clinical diagnosis of sinusitis. Upper respiratory tract infections are often due to viral infection and are the most common causes of antibiotic misuse (11, 12) Tools that can better define patients who may benefit from antibiotics from those who will not, have the potential to significantly impact clinical care and aid in the fight against the threat of antimicrobial resistance (13). While authors did not find significant differences among patients with and without bacterial sinusitis, they showed that point of care testing from a single swab can be used to characterize the local microbiologic and immunologic profile of children with acute illness opening the potential for other tests that may in fact be critical in guiding antibiotic use.

Cystic fibrosis (CF) is a progressive chronic disease caused by recessive genetic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that affects lungs, pancreas, and other organs (14). It is the most common life-threatening inherited disorder of children that affects 1 in 3,300 live births in the world (15). Despite CF being a serious disease that can be associated with early mortality, the epidemiology and disease prognosis have changed in the last 20 years (14). In fact, the survival of CF patients has greatly improved in recent decades. In this topic Castro e Garcia et al. have provided a summary of improvements on diagnostics and therapeutics (16). In this review authors described how basic science research has generated improvements in CF prognosis. Additionally, authors have mentioned the impact of cystic fibrosis transmembrane conductance regulator (CFTR) protein modulators on life expectancy for almost all individuals with CF.

CLCA1 is a member of the CLCA (calcium-activated chloride channel regulator) family, and plays a key role in the pathogenesis of mucus hypersecretory-associated respiratory diseases, such as asthma (17). CLCA1 modulates mucus dynamics and homeostasis in multiple environments, such as intestinal and respiratory epithelia. In this topic, Xu et al. (18) investigated associations between CLCA1 expression and IL-13 levels, which is the main biomarker of airway and blood eosinophilia, a main characteristic of type 2 asthma (19). To this end, the authors designed a full "bench-to-bedside" experimental approach. They showed that CLCA1 expression in epithelial tissue from asthmatic children was significantly increased when compared to *tissue from non-asthmatic* individuals. In addition, asthmatic individuals had increased IL-13 and IL-4 levels. A correlation between CLCA1 and IL-13 levels was then explored *in vitro* showing that IL-13 stimulation upregulates expression of CLCA1. Finally, the potential mechanism of such interactions was explored by siRNA-mediated knockdown of CLCA1, which resulted in attenuation of IL-13 induced bronchial epithelial cell activity and reduction of cell apoptosis. These results strongly suggest that CLCA1-mediated IL-13 may be a key driver in pediatric asthma, paving the way to identify novel potential therapeutic targets in this population.

Manti and Piedimonte provide a comprehensive and up-todate view of a critical association that has come to prominence during the last decades: the link between RSV infection and asthma (20). Although severe RSV infection has been associated with long term complications such as impaired lung function, recurring wheezing and asthma, whether RSV lower respiratory tract infection causally affects the possibility of developing asthma during childhood has not been determined, and the possible mechanisms are poorly characterized (21). In their review article, the authors help organize and bring clarity to this matter by providing a full description of RSV structure including the key players in the host-pathogen interaction, at the cellular, tissular and immunological level. Interestingly, the often-neglected effect of RSV infection on neurological pathways is covered extensively, highlighting multiple cellular mechanisms that impact directly on the dysregulation of the neural control of airway smooth cells and the link with asthma onset. Finally, a thorough description of in vivo and human models for RSV and non-allergic asthma is provided. This section should be of reference for anyone interested in setting up a translational experiment exploring the role of RSV infection and development of asthma, as multiple results obtained from both models are provided, including a critical discussion of the advantages and shortcomings inherent to each specific approach. Finally the authors support a "two-hit" model for the development of RSV-induced asthma involving the co-existence of at least two factors from the trio of individual, developmental, and environmental variables, trying to shed light on the usually contradicting results that look for linear associations between different factors (22).

Author contributions

All authors contributed to the manuscript conception and writing. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their

References

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* (2012) 380:2095–128. doi: 10.1016/S0140-6736(12)61728-0

2. Paggi DA, Polack FP. Toward personalized medicine in bronchiolitis. Am J Respir Crit Care Med. (2019) 199:1456-8. doi: 10.1164/rccm.201812-2371ED

3. Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. *J Allergy Clin Immunol.* (2011) 127:355–60. doi: 10.1016/j.jaci.2010.11.037

4. Polack FP, Stein RT, Custovic A. The syndrome we agreed to call bronchiolitis. J Infect Dis. (2019) 220:184-6. doi: 10.1093/infdis/jiz082

5. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 Mutations are associated with endotoxin hyporesponsiveness in humans. *Nat Genet.* (2000) 25:187–91. doi: 10.1038/76048

6. Caballero MT, Serra ME, Acosta PL, Marzec J, Gibbons L, Salim M, et al. TLR4 Genotype and environmental LPS mediate RSV bronchiolitis through Th2 polarization. J Clin Invest. (2015) 125:571–82. doi: 10.1172/JCI75183

7. Hawlader MDH, Ma E, Noguchi E, Itoh M, Arifeen SE, Persson LA, et al. Ascaris lumbricoids infection as a risk factor for asthma and atopy in rural Bangladeshi children. *Trop Med Health.* (2014) 42:77–85. doi: 10.2149/tmh. 2013-19

8. Palmer LJ, Celedón JC, Weiss ST, Wang B, Fang Z, Xu X. Ascaris lumbricoides infection is associated with increased risk of childhood asthma and atopy in rural China. *Am J Respir Crit Care Med.* (2002) 165:1489–93. doi: 10.1164/rccm.2107020

9. Buendía JA, Lindarte EF, Polack FP. TLR4 Gene polymorphisms interaction with ascaris infection in severe RSV bronchiolitis. *Front Pediatr.* (2022) 10. doi: 10. 3389/fped.2022.876882

10. Lopez SMC, Shaikh N, Johnson M, Liu H, Martin JM, Williams JV. Viral coinfection and nasal cytokines in children with clinically diagnosed acute sinusitis. *Front Pediatr.* (2022) 9. doi: 10.3389/fped.2021.783665

11. van Houten CB, Cohen A, Engelhard D, Hays JP, Karlsson R, Moore E, et al. Antibiotic misuse in respiratory tract infections in children and adults-a prospective, multicentre study (TAILORED treatment). *Eur J Clin Microbiol Infect Dis.* (2019) 38:505–14. doi: 10.1007/s10096-018-03454-2

affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

12. Donnelly JP, Baddley JW, Wang HE. Antibiotic utilization for acute respiratory tract infections in U.S. emergency departments. *Antimicrob Agents Chemother*. (2014) 58:1451-7. doi: 10.1128/AAC.02039-13

13. Barlam TF, Soria-Saucedo R, Cabral HJ, Kazis LE. Unnecessary antibiotics for acute respiratory tract infections: association with care setting and patient demographics. *Open Forum Infect Dis.* (2016) 3:ofw045. doi: 10.1093/ofd/ofw045

14. Scotet V, L'Hostis C, Férec C. The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery. *Genes (Basel)*. (2020) 11:589. doi: 10.3390/genes11060589

15. Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. (2021) 397:2195-211. doi: 10.1016/S0140-6736(20)32542-3

16. Garcia LdeCE, Petry LM, Germani PAVDS, Xavier LF, de Barros PB, Meneses ADS, et al. Translational research in cystic fibrosis: from bench to beside. *Front Pediatr.* (2022) 10. doi: 10.3389/fped.2022.881470

17. Nyström EEL, Birchenough GMH, van der Post S, Arike L, Gruber AD, Hansson GC, et al. Calcium-activated chloride channel regulator 1 (CLCA1) controls mucus expansion in colon by proteolytic activity. *eBioMedicine*. (2018) 33:134–43. doi: 10.1016/j.ebiom.2018.05.031

18. Xu Y, Cao L, Chen J, Jiang D, Ruan P, Ye Q. CLCA1 mediates the regulatory effect of IL-13 on pediatric asthma. *Front Pediatr.* (2022) 10. doi: 10.3389/fped. 2022.959439

19. Demenais F, Margaritte-Jeannin P, Barnes KC, Cookson WOC, Altmüller J, Ang W, et al. Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. *Nat Genet.* (2018) 50:42–53. doi: 10. 1038/s41588-017-0014-7

20. Manti S, Piedimonte G. An overview on the RSV-mediated mechanisms in the onset of non-allergic asthma. *Front Pediatr.* (2022) 10. doi: 10.3389/fped.2022. 998296

21. Esteban I, Stein RT, Polack FP. A durable relationship: respiratory syncytial virus bronchiolitis and asthma past their golden anniversary. *Vaccines (Basel)*. (2020) 8:201. doi: 10.3390/vaccines8020201

22. Knudson CJ, Varga SM. The relationship between respiratory syncytial virus and asthma. *Vet Pathol.* (2015) 52:97–106. doi: 10.1177/0300985814520639